The recent success of immunotherapy targeting programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) in other cancers, such as non-small cell lung cancer and melanoma, has yet to be achieved in TNBC regardless of which monoclonal antibodies (including pembrolizumab, durvalumab, atezolizumab and avelumab) are used [7–15]. This evidence concerns the gene CD274 and cancer.